Infectious Retinitis: Recognizing, Diagnosing, and Treating Retinal Infection

Floaters are among the most commonly reported early symptoms of infectious retinitis. They appear as spots, strands, or drifting shapes in the field of vision. In this setting, they may represent inflammatory cells suspended in the vitreous gel (the clear, jelly-like substance that fills the interior of the eye) or small amounts of bleeding caused by retinal damage.

Blurred or reduced vision is another frequent complaint. The cause may be inflammatory haze inside the eye, direct damage to the macula, or both. Some patients notice a slow, gradual dimming of vision over days or weeks. Others experience a sudden and significant drop in sight. Both patterns deserve prompt evaluation.

Some patients develop red, painful eyes and increased sensitivity to bright light (photophobia). These symptoms are particularly common in viral forms of retinitis, such as acute retinal necrosis. The degree of pain and redness depends on the type of infection and how far it has advanced.

Importantly, not every form of infectious retinitis causes pain. CMV retinitis often progresses in immunocompromised individuals without producing significant discomfort. This silent progression makes scheduled retinal examinations essential for anyone at elevated risk, even when no symptoms are present.

In infants and young children, infectious retinitis may not present the same way it does in adults. Parents may notice that a child's eyes appear crossed, move involuntarily, or reflect an unusual white light through the pupil. Any of these signs should be evaluated by an eye specialist promptly.

In adults, retinal infection sometimes accompanies wider illness. Fever, chills, night sweats, or unintentional weight loss alongside new eye symptoms can provide important clues about the underlying cause and should be discussed with the treating physician.

Treatment intensity and duration vary widely depending on the type of infection and the patient's overall immune health. Some patients require hospitalization for intravenous medication, while others can be managed as outpatients with oral therapy and periodic intravitreal injections. Frequent follow-up visits during active treatment allow our specialists to monitor how the retina is responding, adjust medications when needed, and identify any complications early.

Patients receiving intravitreal injections may notice mild discomfort, temporary redness, or a brief increase in floaters following each procedure. These effects are typically short-lived and resolve within a few days.

How much vision is preserved depends on several factors: which area of the retina was infected, how quickly treatment began, and how well the infection responds to therapy. Infections that involve the macula or optic nerve before treatment begins tend to result in more lasting changes in vision. Retinal tissue that has been destroyed by the infection cannot regenerate.

Patients who begin treatment early, before significant tissue loss has occurred, generally have better visual outcomes. This is why rapid evaluation and prompt initiation of therapy are priorities in every case of infectious retinitis.

Many patients require ongoing retinal monitoring after the active infection has resolved. Viral infections such as CMV and herpes can reactivate, particularly when immune function fluctuates. Patients with HIV should continue scheduled dilated retinal examinations even when feeling well, since CMV retinitis can develop without causing pain or noticeable symptoms in its early stages. Toxoplasmosis can also recur, and any new visual symptoms should prompt immediate contact with a retinal specialist rather than a wait-and-see approach.

Both eyes can be affected, though the likelihood depends on the type of infection. Herpes-related acute retinal necrosis carries a notable risk of spreading to the unaffected eye if treatment is not initiated quickly, which is one reason why antiviral therapy is started urgently. CMV retinitis can also involve both eyes, sometimes simultaneously and sometimes sequentially over weeks or months. This is why both eyes are monitored throughout and after treatment, not only the one initially identified as infected. If any symptoms develop in the second eye, prompt re-evaluation is essential rather than waiting for a scheduled visit.

The retinal infection itself does not spread from person to person through everyday contact. However, the underlying organisms can be transmitted in other ways. CMV spreads through bodily fluids including saliva and blood. Toxoplasma can be acquired through contact with infected cat feces or by eating undercooked meat. Syphilis is a sexually transmitted infection. Understanding how the systemic infection spreads is important for protecting household members and partners, even though the retinal complication itself does not transfer directly between individuals.

During active treatment, visits may be scheduled as frequently as every one to two weeks so our team can monitor how the retina is responding and adjust therapy as needed. Once the infection is controlled, the interval between appointments typically lengthens to every few months. Patients with ongoing immune compromise, such as those managing HIV or taking long-term immunosuppressive therapy, generally need lifelong periodic retinal examinations because the risk of reactivation does not disappear after successful treatment. The specific schedule is tailored to each patient's situation and may change over time based on immune status and retinal findings.

Whether vision can be regained depends on the location and extent of retinal damage. Retinal tissue that has been destroyed by the infection does not regenerate, so treatment is focused on stopping further loss as quickly as possible. If infection is identified and treated before the macula or optic nerve has sustained significant damage, meaningful vision may be preserved. When some permanent sight loss has already occurred, low vision rehabilitation can help patients adapt and maintain independence in daily activities. The most important factor affecting outcome is how soon effective treatment is started, which underscores the urgency of evaluation at first symptoms.

There is currently no vaccine designed specifically to prevent infectious retinitis. However, the shingles vaccine substantially reduces the risk of herpes zoster reactivation, which in turn lowers the chance of developing herpes-related retinal disease. Research into vaccines for CMV and Toxoplasma is ongoing, but none have been approved for routine clinical use at this time. For most patients at elevated risk, preventive strategies center on maintaining immune health, reducing known pathogen exposures, and ensuring regular monitoring so that any infection can be identified and treated at the earliest possible stage.